Oncolytics Biotech Inc (ONC) - Financial and Strategic SWOT Analysis Review
Oncolytics Biotech Inc (ONC) Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Oncolytics Biotech Inc (Oncolytics Biotech) is a development stage biopharmaceutical company which focuses on the discovery and development of oncolytic viruses for the treatment of cancer. The company’s lead product candidate, pelareorep, is an unmodified reovirus that is an intraosseous (I-O) viral agent indicated for systemic administration for the treatment of hematological malignancies and solid tumors. The company is advancing pelareorep as a combination with other products in various clinical phases for the treatment of metastatic breast cancer (BC), early stage BC, pancreatic cancer, and relapsed or refractory multiple myeloma. It is advancing its pipeiline in collaboration with PrECOG LLC, KGaA, Darmstadt, and Pfizer to advance its clinical trials for the treatment of cancer. Oncolytics Biotech is headquartered in Calgary, Alberta, Canada.
Oncolytics Biotech Inc Key Recent Developments
Jul 22,2021: Oncolytics Biotech to Host Conference Call to Discuss Second Quarter Financial Results and Operational Highlights
May 10,2021: Oncolytics Biotech Announces Voting Results from the Annual General Meeting of Shareholders
May 07,2021: Oncolytics Biotech® Reports 2021 First Quarter Development Highlights and Financial Results
Apr 30,2021: Oncolytics Biotech Announces Annual General Meeting
Apr 29,2021: Oncolytics Biotech Announces Upcoming Presentation at the American Society of Clinical Oncology Annual Meeting
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Oncolytics Biotech Inc (Oncolytics Biotech) is a development stage biopharmaceutical company which focuses on the discovery and development of oncolytic viruses for the treatment of cancer. The company’s lead product candidate, pelareorep, is an unmodified reovirus that is an intraosseous (I-O) viral agent indicated for systemic administration for the treatment of hematological malignancies and solid tumors. The company is advancing pelareorep as a combination with other products in various clinical phases for the treatment of metastatic breast cancer (BC), early stage BC, pancreatic cancer, and relapsed or refractory multiple myeloma. It is advancing its pipeiline in collaboration with PrECOG LLC, KGaA, Darmstadt, and Pfizer to advance its clinical trials for the treatment of cancer. Oncolytics Biotech is headquartered in Calgary, Alberta, Canada.
Oncolytics Biotech Inc Key Recent Developments
Jul 22,2021: Oncolytics Biotech to Host Conference Call to Discuss Second Quarter Financial Results and Operational Highlights
May 10,2021: Oncolytics Biotech Announces Voting Results from the Annual General Meeting of Shareholders
May 07,2021: Oncolytics Biotech® Reports 2021 First Quarter Development Highlights and Financial Results
Apr 30,2021: Oncolytics Biotech Announces Annual General Meeting
Apr 29,2021: Oncolytics Biotech Announces Upcoming Presentation at the American Society of Clinical Oncology Annual Meeting
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
SECTION 1 - ABOUT THE COMPANY
Oncolytics Biotech Inc - Key Facts
Oncolytics Biotech Inc - Key Employees
Oncolytics Biotech Inc - Key Employee Biographies
Oncolytics Biotech Inc - Major Products and Services
Oncolytics Biotech Inc - History
Oncolytics Biotech Inc - Company Statement
Oncolytics Biotech Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
Oncolytics Biotech Inc - Business Description
R&D Overview
Oncolytics Biotech Inc - Corporate Strategy
Oncolytics Biotech Inc - SWOT Analysis
SWOT Analysis - Overview
Oncolytics Biotech Inc - Strengths
Oncolytics Biotech Inc - Weaknesses
Oncolytics Biotech Inc - Opportunities
Oncolytics Biotech Inc - Threats
Oncolytics Biotech Inc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Oncolytics Biotech Inc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Jul 22, 2021: Oncolytics Biotech to Host Conference Call to Discuss Second Quarter Financial Results and Operational Highlights
May 10, 2021: Oncolytics Biotech Announces Voting Results from the Annual General Meeting of Shareholders
May 07, 2021: Oncolytics Biotech® Reports 2021 First Quarter Development Highlights and Financial Results
Apr 30, 2021: Oncolytics Biotech Announces Annual General Meeting
Apr 29, 2021: Oncolytics Biotech Announces Upcoming Presentation at the American Society of Clinical Oncology Annual Meeting
Mar 10, 2021: Oncolytics Biotech® Announces Upcoming Presentations at the AACR Annual Meeting
Feb 26, 2021: Oncolytics Biotech to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Operational Highlights
Nov 11, 2020: Oncolytics Biotech reports 2020 third quarter development highlights and financial results
Nov 06, 2020: Oncolytics Biotech to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights
Oct 22, 2020: Clinical Trials delivering new optimism in fight against triple-negative breast cancer
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
Oncolytics Biotech Inc - Key Facts
Oncolytics Biotech Inc - Key Employees
Oncolytics Biotech Inc - Key Employee Biographies
Oncolytics Biotech Inc - Major Products and Services
Oncolytics Biotech Inc - History
Oncolytics Biotech Inc - Company Statement
Oncolytics Biotech Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
Oncolytics Biotech Inc - Business Description
R&D Overview
Oncolytics Biotech Inc - Corporate Strategy
Oncolytics Biotech Inc - SWOT Analysis
SWOT Analysis - Overview
Oncolytics Biotech Inc - Strengths
Oncolytics Biotech Inc - Weaknesses
Oncolytics Biotech Inc - Opportunities
Oncolytics Biotech Inc - Threats
Oncolytics Biotech Inc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Oncolytics Biotech Inc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Jul 22, 2021: Oncolytics Biotech to Host Conference Call to Discuss Second Quarter Financial Results and Operational Highlights
May 10, 2021: Oncolytics Biotech Announces Voting Results from the Annual General Meeting of Shareholders
May 07, 2021: Oncolytics Biotech® Reports 2021 First Quarter Development Highlights and Financial Results
Apr 30, 2021: Oncolytics Biotech Announces Annual General Meeting
Apr 29, 2021: Oncolytics Biotech Announces Upcoming Presentation at the American Society of Clinical Oncology Annual Meeting
Mar 10, 2021: Oncolytics Biotech® Announces Upcoming Presentations at the AACR Annual Meeting
Feb 26, 2021: Oncolytics Biotech to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Operational Highlights
Nov 11, 2020: Oncolytics Biotech reports 2020 third quarter development highlights and financial results
Nov 06, 2020: Oncolytics Biotech to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights
Oct 22, 2020: Clinical Trials delivering new optimism in fight against triple-negative breast cancer
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
LIST OF TABLES
Oncolytics Biotech Inc, Key Facts
Oncolytics Biotech Inc, Key Employees
Oncolytics Biotech Inc, Key Employee Biographies
Oncolytics Biotech Inc, Major Products and Services
Oncolytics Biotech Inc, History
Oncolytics Biotech Inc, Other Locations
Oncolytics Biotech Inc, Subsidiaries
Oncolytics Biotech Inc, Key Competitors
Oncolytics Biotech Inc, Ratios based on current share price
Oncolytics Biotech Inc, Annual Ratios
Oncolytics Biotech Inc, Annual Ratios (Cont...1)
Oncolytics Biotech Inc, Interim Ratios
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Oncolytics Biotech Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
Oncolytics Biotech Inc, Key Facts
Oncolytics Biotech Inc, Key Employees
Oncolytics Biotech Inc, Key Employee Biographies
Oncolytics Biotech Inc, Major Products and Services
Oncolytics Biotech Inc, History
Oncolytics Biotech Inc, Other Locations
Oncolytics Biotech Inc, Subsidiaries
Oncolytics Biotech Inc, Key Competitors
Oncolytics Biotech Inc, Ratios based on current share price
Oncolytics Biotech Inc, Annual Ratios
Oncolytics Biotech Inc, Annual Ratios (Cont...1)
Oncolytics Biotech Inc, Interim Ratios
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Oncolytics Biotech Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
LIST OF FIGURES
Oncolytics Biotech Inc, Performance Chart (2016 - 2020)
Oncolytics Biotech Inc, Ratio Charts
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021
Oncolytics Biotech Inc, Performance Chart (2016 - 2020)
Oncolytics Biotech Inc, Ratio Charts
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021